Kymera Therapeutics (KYMR) Accounts Payables (2019 - 2026)

Kymera Therapeutics (KYMR) has 8 years of Accounts Payables data on file, last reported at $12.8 million in Q1 2026.

• On a quarterly basis, Accounts Payables rose 25.1% year-over-year to $12.8 million in Q1 2026; TTM through Mar 2026 was $12.8 million, a 25.1% increase from a year earlier, with the FY2025 full-year figure at $4.0 million, down 32.96% from the prior year.
• Accounts Payables for Q1 2026 stood at $12.8 million, up from $4.0 million in the prior quarter.
• Over the last five years, Accounts Payables for KYMR reached as high as $12.8 million in Q1 2026 and fell as low as $2.4 million in Q2 2022.
• Historically, Accounts Payables has averaged $6.0 million across 5 years, with a median of $6.0 million in 2024.
• Across the five-year window, Accounts Payables tumbled 70.97% in 2022 and jumped 152.55% in 2023, its largest moves.
• Year by year, Accounts Payables stood at $4.3 million in 2022, then soared by 63.21% to $7.1 million in 2023, then slipped by 15.35% to $6.0 million in 2024, then sank by 32.96% to $4.0 million in 2025, then soared by 219.78% to $12.8 million in 2026.
• Per Business Quant data, the three most recent Accounts Payables figures were $12.8 million in Q1 2026, $4.0 million in Q4 2025, and $5.5 million in Q3 2025.